4/A: Unicycive CEO Shalabh Gupta Receives RSU Grant

Unicycive Therapeutics CEO Shalabh Gupta was granted 762,200 restricted stock units as part of a compensation package.

Summary

• CEO Shalabh Gupta received a grant of 762,200 restricted stock units (RSUs) on May 14, 2026.
• The RSU award is payable solely in common stock of Unicycive Therapeutics, Inc.
• 105,861 shares vested immediately upon the grant date.
• The remaining 656,339 shares vest over a 31-month period beginning June 1, 2026, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that carries no immediate impact on the company's financial trajectory.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention mechanism established via a 31-month vesting schedule for the majority of the grant.

Negatives

• Potential for future shareholder dilution upon the conversion of RSUs into common stock.

Risks

• Dependence on the continued service of the CEO to fulfill the vesting requirements.
• Market volatility affecting the ultimate value of the equity compensation.

Future Outlook

The grant indicates a commitment to executive retention through mid-2028, aligning the CEO's incentives with the company's long-term operational milestones.

Management Comments

• The RSU award is payable solely in common stock of the Issuer.

Industry Context

StockSavvy.ai notes that equity-based compensation remains the standard for biotech leadership to preserve cash while incentivizing long-term clinical and regulatory success.

Comparison to Industry Standards

• The use of multi-year vesting schedules for executive equity is consistent with standard corporate governance practices in the biotechnology sector.
• Granting RSUs to CEOs is a common practice among small-cap biotech firms to manage cash burn.

Stakeholder Impact

• Shareholders may experience minor dilution as these RSUs vest and convert to common stock.

Next Steps

• Vesting of remaining shares over 31 months starting June 1, 2026.

Key Dates

Keywords

Unicycive Therapeutics, UNCY, Shalabh Gupta, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units